IN8bio (NASDAQ:INAB) Issues Quarterly Earnings Results, Beats Expectations By $0.03 EPS

IN8bio (NASDAQ:INAB) issued its quarterly earnings data on Thursday. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.03, Zacks reports.

IN8bio Trading Down 0.4 %

IN8bio stock opened at $0.23 on Friday. The stock has a 50-day simple moving average of $0.28 and a 200 day simple moving average of $0.30. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.84 and a current ratio of 1.84. The stock has a market capitalization of $18.32 million, a P/E ratio of -0.30 and a beta of 0.03. IN8bio has a 52 week low of $0.21 and a 52 week high of $1.74.

Wall Street Analyst Weigh In

Separately, HC Wainwright lowered their target price on IN8bio from $8.00 to $6.00 and set a “buy” rating for the company in a report on Friday.

IN8bio Company Profile

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.